PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

With autumn weather finally here and spooky season upon us, there’s no better time – in our humble opinion – to curl up with a great new book. October brings with it a blockbuster month of new ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

LIVE BLOG: The latest news on all the deals that are still live after October Prime Day 2024 UPDATE: Oct. 10, 2024, 7:10 a.m. EDT This post has been updated with the latest Amazon book deals on Pr ...

Former U.K. foreign aid officials' advice to Prime Minister Keir Starmer. Plus time is running out for the U.N.'s “failing ...

This move aligns with Gilead's strategy to broaden access to the medication for pre-exposure prophylaxis (PrEP) and treatment for heavily treatment-experienced adults with multi-drug resistant HIV.

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...